Lilly to acquire Ajax Therapeutics to advance next-gen JAK2 therapy for myeloproliferative neoplasms
Lilly has a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion in cash to accelerate AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for myeloproliferative neoplasms (myelofibrosis and polycythemia vera). AJ1-11095 is designed to bind a different JAK2 conformation for deeper, more durable efficacy and tolerability, with clinical proof-of-concept data expected later in 2026 and plans to move into registrational trials across first- and second-line settings.
